APL-5125 (Gastrointestinal Cancers) - Clinical Trial
¿Cuál es el Propósito de este estudio?
We are doing this study to find out if an experimental drug called APL-5125 (the study drug) is a safe and effective for people with select types of gastrointestinal cancer. We are also trying to find the best dose of APL-5125 to use.
¿Cuál es la Condición que se está estudiando?
Cánceres gastrointestinales
¿Quién puede participar en el Estudio?
Adults ages 18+ who have locally advanced or metastatic tumors of one of the following types:
- Colorectal carcinoma
- Colangiocarcinoma
- Appendiceal adenocarcinoma
For more information about this study, contact the study team at 919-668-1861.
Grupo etario
Adultos
¿Qué Implica?
Si elige unirse a este estudio, podrá:
- Take the study drug, APL-5125, by mouth every day
- Hágase biopsia del tumor
- Give blood and urine samples
- Realice tomografías computarizadas o resonancias magnéticas de manera regular.
Detalles del Estudio
Título Completo
[AP10CP01] A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults with Selected Advanced Solid Tumors
Investigador Principal
John H. Strickler, MD
Especialista en oncología médica
Número de Protocolo
IRB:
PRO00115529
NCT:
NCT06399757
Fase
Phase
I/II
ClinicalTrials.gov
Ver en ClinicalTrials.gov
Estado de inscripción
Abierto para inscripción
Participate
Call 919-668-1861
or email gi-oncology-cru@dm.duke.edu